A Randomized, Double-Masked, Placebo-Controlled Study to Assess the Efficacy and Safety of REGN5713-5715 to Reduce Signs and Symptoms of Allergic Conjunctivitis in Participants With Birch Pollen Allergy

This study is researching 2 experimental drugs, REGN5713 and REGN5715, which are called REGN5713-5715 when mixed together (called "study drug(s)") to reduce eye allergy signs and symptoms due to birch tree pollen allergy.
The aim of the study is to see how safe and effective the study drug is at lowering allergic eye signs and symptoms compared with placebo. A placebo looks like a treatment but does not contain any real medicine.
The study is looking at several other research questions, including:
* What side effects may happen from taking the study drug
* How much study drug is in the blood at different times
* Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects).

开始日期2024-10-15

申办/合作机构

Regeneron Pharmaceuticals, Inc.

NCT05430919 / Completed临床2期

A Two-Part Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of the Anti-Bet v 1 Monoclonal Antibodies to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen

Primary objective: To assess the efficacy of a single dose of the anti- Bet v 1 monoclonal antibodies (mAb(s ) in the reduction of allergic nasal symptoms during an out-of-season birch allergen environmental exposure unit (EEU) challenge in participants receiving REGN5713-5714-5715 versus placebo (Part A)

开始日期2022-08-15

申办/合作机构

Regeneron Pharmaceuticals, Inc.

NCT04709575 / Completed临床3期

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy of Anti-Bet v 1 Monoclonal Antibodies to Reduce Symptoms of Seasonal Allergic Rhinitis

The primary objective is to assess the reduction of allergic symptoms as measured by combined symptom and medication score (CSMS) during birch pollen season after a single dose of REGN5713-5714-5715 versus placebo.

开始日期2021-01-14

申办/合作机构

Regeneron Pharmaceuticals, Inc.

100 项与 REGN-5713 相关的临床结果

登录后查看更多信息

100 项与 REGN-5713 相关的转化医学

登录后查看更多信息

100 项与 REGN-5713 相关的专利（医药）

登录后查看更多信息

100 项与 REGN-5713 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
过敏	临床3期	-	Regeneron Pharmaceuticals, Inc.	2024-10-15
变应性结膜炎	临床3期	-	Regeneron Pharmaceuticals, Inc.	2024-10-15
结膜炎	临床3期	美国	Regeneron Pharmaceuticals, Inc.	2021-01-14
结膜炎	临床3期	比利时	Regeneron Pharmaceuticals, Inc.	2021-01-14
结膜炎	临床3期	加拿大	Regeneron Pharmaceuticals, Inc.	2021-01-14
结膜炎	临床3期	丹麦	Regeneron Pharmaceuticals, Inc.	2021-01-14
结膜炎	临床3期	德国	Regeneron Pharmaceuticals, Inc.	2021-01-14
季节性过敏性鼻炎	临床3期	美国	Regeneron Pharmaceuticals, Inc.	2021-01-14
季节性过敏性鼻炎	临床3期	比利时	Regeneron Pharmaceuticals, Inc.	2021-01-14
季节性过敏性鼻炎	临床3期	加拿大	Regeneron Pharmaceuticals, Inc.	2021-01-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04709575 (CTgov)	临床3期	季节性过敏性鼻炎 \| 结膜炎	353	REGN5715+REGN5714+REGN5713 (REGN5713-5714-5715)	膚築範構遞遞構糧淵繭(網壓觸選鹽鬱範夢齋獵) = 蓋壓繭醖艱鏇壓醖顧餘餘觸築觸積顧製顧糧網 (簾淵觸築齋鏇衊鬱獵夢, 鏇艱製遞鏇製遞觸壓網 ~ 鏇膚壓蓋壓窪築鏇夢夢) 更多	-	2022-10-27
				Placebo (Placebo Only)	膚築範構遞遞構糧淵繭(網壓觸選鹽鬱範夢齋獵) = 築衊餘選夢網鑰壓遞願餘觸築觸積顧製顧糧網 (簾淵觸築齋鏇衊鬱獵夢, 壓築齋艱鏇鬱積夢遞襯 ~ 膚築築糧獵壓簾遞鬱餘) 更多